IP Library Granted Patent US 7,091,325
Granted Patent B2
US 7,091,325 · App. 10/749,832 · Granted Aug 15, 2006

Fibrin/fibrinogen-binding conjugate

Assignees: Baxter Aktiengesellschaft; Baxter International Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,091,325
App. No.
10/749,832
Granted
Aug 15, 2006
Kind
B2
Abstract

A fibrin/fibrinogen binding conjugate for forming a depot for the sustained release of a pharmaceutically active substance from a fibrin clot. The conjugate comprises a fibrin/fibrinogen binding moiety bound to a pharmaceutically active substance either directly or via an intervening substance capturing moiety such as an antibody. The conjugate can also be a recombinant fusion protein comprising a fibrin/fibrinogen binding moiety such as VEGF 165 C-terminal domain fused to a wound-healing substance such as leptin.

Claims (23)

1. Fibrin/fibrinogen-binding conjugate comprising

a fibrin/fibrinogen-binding moiety that is a nucleic acid,

a substance capturing moiety capable of reversibly binding to a pharmaceutically active substance,

wherein said fibrin/fibrinogen-binding moiety is bound to said substance capturing moiety.

2. The conjugate of claim 1 , wherein said substance capturing moiety is an antibody, a receptor or a part thereof which specifically recognizes said pharmaceutically active substance.

3. The conjugate of claim 1 , further comprising a pharmaceutically active substance.

4. The conjugate of claim 3 , wherein said pharmaceutically active substance is selected from the group consisting of antibiotics, growth factors, receptors for tissue components, tissue adhesive substances, nucleic acids, plasma proteins, hormones, heparinoids, wound-healing substances, and imaging agents.

5. The conjugate of claim 1 , wherein said fibrin/fibrinogen-binding moiety and said substance capturing moiety are covalently bound.

6. Fibrin/fibrinogen-binding conjugate comprising

a fibrin/fibrinogen-binding moiety selected from the group consisting of fibronectin, bacterial fibrinogen binding proteins, integrins, and moieties derived from any member of this group,

a substance capturing moiety that is an antibody or a part thereof which specifically recognizes a pharmaceutically active substance, and

the pharmaceutically active substance,

wherein said fibrin/fibrinogen-binding moiety is bound to said substance capturing moiety.

7. Fibrin/fibrinogen-binding conjugate comprising

a fibrin/fibrinogen-binding moiety selected from the group consisting of fibronectin, bacterial fibrinogen binding proteins, integrins, and moieties derived from any member of this group,

a substance capturing moiety that is an antibody or a part thereof which specifically recognizes a pharmaceutically active substance,

wherein said fibrin/fibrinogen-binding moiety is bound to said substance capturing moiety.

8. The conjugate of claim 6 , wherein said pharmaceutically active substance is selected from the group consisting of antibiotics, growth factors, receptors for tissue components, tissue adhesive substances, nucleic acids, plasma proteins, hormones, heparinoids, and imaging agents.

9. The conjugate of claim 6 , wherein said fibrin/fibrinogen-binding moiety and said substance capturing moiety are covalently bound.

10. The conjugate of claim 6 , wherein said pharmaceutically active substance is a wound healing substance.

11. The conjugate of claim 7 , wherein said fibrin/fibrinogen-binding moiety and said substance capturing moiety are covalently bound.

12. The conjugate of claim 7 wherein said pharmaceutically active substance is selected from the group consisting of antibiotics, growth factors, receptors for tissue components, tissue adhesive substances, nucleic acids, plasma proteins, hormones, heparinoids, and imaging agents.

13. The conjugate of claim 7 , wherein said pharmaceutically active substance is a wound healing substance.

Assignments (7)
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNOR AND ASSIGNEE NAME AND ADDRESS OF BAXTER HEALTHCARE S.A. PREVIOUSLY RECORDED ON REEL 035414 FRAME 0425. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Apr 19, 2016
From: BAXALTA INNOVATIONS GMBH
To: BAXTER INTERNATIONAL INC.; BAXTER HEALTHCARE SA
Reel/Frame 038461/0884 →
CHANGE OF NAME Recorded Apr 12, 2016
From: BAXTER INNOVATIONS GMBH
To: BAXALTA INNOVATIONS GMBH
Reel/Frame 038414/0557 →
CHANGE OF NAME Recorded Apr 8, 2016
From: BAXTER TRADING GMBH
To: BAXTER INNOVATIONS GMBH
Reel/Frame 038399/0295 →
CHANGE OF NAME Recorded Apr 8, 2016
From: BAXTER AKTIENGESELLSCHAFT
To: BAXTER EASTERN EUROPE VERTRIEBS GMBH
Reel/Frame 038399/0281 →
CHANGE OF NAME Recorded Apr 8, 2016
From: BAXTER EASTERN EUROPE VERTRIEBS GMBH
To: BAXTER TRADING GMBH
Reel/Frame 038399/0287 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 15, 2015
From: BAXTER AKTIENGESELLSCHAFT
To: BAXTER HEALTHCARE S.A.; BAXTER INTERNATIONAL INC.
Reel/Frame 035414/0425 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 27, 2006
From: REDL, HEINZ; FUERST, WALTER; KNEIDINGER, RUDOLF; HELGERSON, SAM L.; LOOKER, DOUGLAS; INMAN, ELISABETH M.; RICHARDS, JANE P.; WONG, CATALINA
To: BAXTER AKTIENGESELLSCHAFT; BAXTER INTERNATIONAL INC.
Reel/Frame 017370/0687 →
Continuity (3)
Continuation 0996315600 · Sep 25, 2001
Continuation In Part 0966924000 · Sep 25, 2000
Related Publication 20040191261A1 · Sep 30, 2004